ClinicalTrials.gg
RecruitingNCT07020065Updated Oct 28, 2026

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

A Phase 2 interventional study of Cemiplimab and Carboplatin in Metastatic NSCLC - Non-Small Cell Lung Cancer, sponsored by Swiss Cancer Institute. Recruiting at 18 sites in Switzerland. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Swiss Cancer Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 28, 20266 sites added5 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 40 under way, 12 of them phase 3. Carboplatin · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
54th of 251
156 · median 55
Started
2026
with 5 others
Phase 2
149 of 272
11 open now
Primary completion
2028-09
later than 30 of 39 live
Registered
264th of 272
by date

Among the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, this one is the 54th largest by planned enrollment of the 251 interventional ones that give a count, is one of 6 that started in 2026, is one of 149 in phase 2, reaches primary completion later than 30 of the 39 other live ones, and was the 264th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Metastatic non-small cell lung cancer is often treated with a combination of chemotherapy and immunotherapy. In patients over the age of 70, some are already in poor health and frail, requiring assistance with daily activities, for example. Older and/or frail individuals often do not tolerate standard-dose chemotherapy well, and their risk of side effects is higher than that of younger patients.

For this reason, the SAKK 18/24 study is investigating how effective and safe chemotherapy is in patients over 70 years of age when the chemotherapy drugs are administered at lower doses than usual. The aim of the study is to find a potentially effective and well-tolerated treatment for older people with metastatic non-small cell lung cancer.

Read the detailed description

This randomized, open-label, phase II clinical trial evaluates the efficacy, safety, and overall treatment utility of reduced-dose platinum-doublet chemotherapy (rdCT) in combination with cemiplimab (cemi) versus cemiplimab monotherapy in older and/or frail patients with stage III/IV non-small cell lung cancer (NSCLC) and PD-L1 expression \<50%. The study specifically addresses a major evidence gap for a vulnerable patient population often underrepresented in registrational trials.

Cemiplimab in combination with full-dose carboplatin-based doublet chemotherapy is a Swissmedic-approved first-line treatment for advanced NSCLC, based on data from EMPOWER-Lung 03. However, full-dose chemotherapy regimens (e.g., carboplatin AUC 5 + pemetrexed, paclitaxel, or gemcitabine) are frequently associated with prohibitive toxicity in elderly and/or frail patients. Over half of all newly diagnosed mNSCLC cases occur in individuals aged 70 or older, many of whom present with frailty or multimorbidity. While atezolizumab monotherapy has shown a survival benefit over single-agent chemotherapy in older, treatment-ineligible patients (IPSOS trial), overall outcomes remain suboptimal.

In clinical practice, rdCT regimens are commonly used in this patient population, despite limited prospective evidence. The present study uses the G8 screening tool-a validated geriatric assessment instrument-to identify patients at risk for increased treatment toxicity and to support treatment adaptation.

Objectives The primary objective is to compare overall survival (OS) between rdCT + cemiplimab and cemiplimab monotherapy. Secondary objectives include comparison of progression-free survival (PFS), objective response rate (ORR), adverse events (AE), health-related quality of life (HRQoL), and overall treatment utility (OTU).

Design and Interventions This is a multicenter, randomized, open-label, parallel-group study enrolling approximately 156 patients (78 per arm) across \~17 sites in Switzerland. Eligible patients are ≥70 years old, have a G8 score ≤14 or are deemed unsuitable for full-dose chemotherapy, and have advanced or metastatic NSCLC without actionable genomic alterations and PD-L1 \<50%.

Patients are randomized to one of two arms:

  • Experimental Arm: rdCT + cemiplimab
  • Control Arm: cemiplimab monotherapy Patients who progress and are deemed suitable may cross over to receive rdCT + cemiplimab.

Cemiplimab maintenance continues until disease progression, unacceptable toxicity, or a maximum of 2 years. Treatment beyond progression is permitted in cases of oligoprogression amenable to local therapy.

Assessments Radiologic response assessments (CT ± CNS imaging) are performed every 6 weeks until week 12, then every 9 weeks until week 30, and every 12 weeks thereafter. HRQoL is assessed using NFLSI-17 and QLQ-ELD14 at baseline, every 6 weeks to week 12, every 9 weeks to week 30, and every 24 weeks thereafter.

Overall Treatment Utility (OTU) is assessed at the same intervals and incorporates:

  • Radiological and clinical disease progression
  • Toxicity profile and serious adverse events
  • Patient-reported treatment acceptability Geriatric-specific assessments (hand-grip strength and timed up-and-go) are performed at baseline, week 12, week 30, and every 24 weeks.

Statistical Considerations With 128 OS events, the study is powered (80%) to detect an increase in median OS from 10.3 months (based on IPSOS trial) to 16 months in the experimental arm (one-sided alpha = 0.05). Sample size: 156 patients (allowing 5% attrition).

Time-to-event outcomes will be analyzed using Kaplan-Meier methods with log-rank tests and Cox proportional hazards models. Response rates and adverse events will be compared using Fisher's exact or chi-square tests. Continuous variables (e.g., HRQoL scores) will be analyzed using Wilcoxon rank-sum or linear regression (mixed models as appropriate).

Quality Assurance and Data Integrity

Although not formally a registry, the trial employs registry-like quality control elements:

  • Data validation: Real-time data entry into electronic case report forms (eCRFs) with predefined logic and range checks.
  • Source Data Verification (SDV): Conducted to ensure data accuracy and completeness via comparison with medical records and source documents.
  • Standard Operating Procedures: SOPs are implemented, which cover all trial operations-site initiation, data collection, patient assessments, safety reporting, and amendment handling.
  • Monitoring and auditing: Central and on-site monitoring according to a risk-based monitoring plan. Sites may be audited for compliance with ICH-GCP.
  • Missing data management: Missing values due to dropout, nonresponse, or data inconsistency will be handled using pre-specified strategies, including sensitivity analyses.

Conclusion This trial responds to the pressing need for evidence-based, tolerable, and effective treatment strategies for older and/or frail patients with advanced NSCLC. By leveraging geriatric screening tools and integrating real-world adaptations such as reduced-dose chemotherapy, this study aims to optimize oncologic outcomes while preserving quality of life and functional status. Findings will inform clinical decision-making for a frequently excluded patient group in oncology research.

03

Conditions studied

  • Metastatic NSCLC - Non-Small Cell Lung Cancer

Keywords

  • Reduced-dose chemotherapy
  • Cemiplimab
  • carboplatin
  • metastatic NSCLC
  • PD-L1 <50%
  • Non-Small Cell Lung Cancer
  • older and frail patients
  • phase II
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature
  • or cytologically confirmed NSCLC. Mixed histology with small-cell component is not allowed.
  • or advanced or recurrent NSCLC without a curative-intent treatment option (surgery or chemo-radiotherapy).
  • \<50% by local testing (SP 142 excluded)
  • ≥70 years
  • 0-2
  • G8 screening score of ≤14 and/or ineligible for full-dose chemotherapy, defined as doses of carboplatin AUC 5, pemetrexed 500 mg/m2, paclitaxel 175 mg/m2, gemcitabine 1200 mg/m2 (as per Investigator)
  • ≥6 months
  • Patients with a prior (except NSCLC, see EC 7.2.2 and 7.2.3) and treated with curative intent are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence, after consultation with CI.
  • Patients with asymptomatic untreated or symptomatic treated are eligible if dose \<10 mg prednisolone equivalent/day for at least 7 days
  • Patients must be suitable to receive reduced-dose carboplatin-doublet chemotherapy in combination with immunotherapy including adequate bone marrow, renal and hepatic function as follows:

    • ≥90 g/L, neutrophils ≥1.5 G/L, ≥100G/L
    • (Cockroft-Gault) ≥30 mL/min
    • ASAT/ALAT ≤2xULN, ≤1.5xULN (≤3xULN for patients with Gilbert's disease),
  • Men agree not to donate sperm or father a child during trial treatment and until 6 months after the last dose of trial treatment

Exclusion criteria

Exclusion Criteria:

  • Actionable genomic alteration for 1L treatment (EGFR, ALK, ROS1, RET, NTRK, MET Exon14 skipping). Testing is required for any NSQ-NSCLC or patients with SCC and a smoking history of ≤10py.
  • Prior systemic treatment for NSCLC.
  • Prior chemotherapy and/or immunotherapy in curative-intent treatment for locally advanced NSCLC in the past 6 months.
  • Oligometastatic treatment concept with induction systemic therapy and planned LAT to all lesions.
  • High tumor burden with a risk of rapid critical progression, as judged by the Investigator. Careful patient selection is important in order to prevent that patients in the comparator arm are not eligible for receiving add-on reduced-dose chemotherapy anymore if primary progression occurs (e.g., pericardial infiltration, high liver metastasis load etc).
  • Active, treatment-requiring auto-immune disease in the past 2 years other than vitiligo, alopecia, hypothyroidism, type 1 diabetes or diet-controlled celiac disease.
  • History of pneumonitis in the past 5 years.
  • Systemic treatment ≥10 mg/day of prednisolone-equivalent or any other systemic medication within 7 days prior to first dose of study intervention (except as needed for chemotherapy premedication or for physiologic corticosteroid replacement)
  • Any infection requiring hospitalization or treatment with IV anti-infectives within 2 weeks of first dose of study medication
  • Uncontrolled infection with , or infection
  • Receipt of a within 4 weeks of start of study medication
  • Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication
  • Organ transplant
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Experimental arm

    Non-squamous histology: * carboplatin IV AUC 3 day 1 * pemetrexed IV 300 mg/m2 day 1 * cemiplimab IV 350 mg, day 1 Every 3 weeks, for 4 cycles, followed by maintenance treatment with cemiplimab with or without pemetrexed (at same dose and interval as above). Squamous histology: * carboplatin IV AUC 1.5 day 1, d8 * gemcitabine IV 600 mg/m2 day 1, d8 * cemiplimab IV 350 mg, day 1 Every 3 weeks, for 4 cycles, followed by maintenance treatment with cemiplimab (350 mg q3w) Any histology: * carboplatin IV AUC 1.5 day 1, d8 * paclitaxel IV 50 mg/m2 day 1, d8 * cemiplimab IV 350 mg, day 1 Every 3 weeks, for 4 cycles, followed by maintenance treatment with cemiplimab (350 mg q3w)

    Drug: Cemiplimab · Drug: Carboplatin · Drug: Pemetrexed & Gemcitabine · Drug: Paclitaxel

  • Active comparator
    Comparator arm

    cemiplimab IV 350 mg, day 1 Every 3 weeks (max. 2 years)

    Drug: Cemiplimab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as time from randomization to confirmed tumor progression according to RECIST 1.1 or death due to any cause. Patients not experiencing an event will be censored at their last tumor assessment before starting a new anti-cancer treatment line (if any).

    Time frame: From the date of randomization until the date of confirmed tumor progression according to RECIST 1.1 or death from any cause, assessed up to 1 year after end of treatment.

Secondary outcomes

  1. Overall survival (OS)

    OS is defined as time from randomization to death due to any cause. Patients not experiencing an event will be censored at their last date known alive.

    Time frame: From the date of randomization until the date of death from any cause, assessed up to 1 year after end of treatment.

  2. Objective response rate (ORR)

    Objective response is defined as any complete response (CR) or partial response (PR) according to RECIST 1.1 criteria achieved during treatment. Patients without any tumor assessment or with non-evaluable response during treatment will be considered as failures for this endpoint

    Time frame: From the date of randomization until the end of treatment, estimated up to 1 year after randomization.

07

Study locations

18 of 18 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2028, 29 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 29 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 13, 2025
StartActual
Apr 10, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2030
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 5 sites removed
Show 6 added (6 Switzerland)
  • EOC Istituto Oncologico della Svizzera Italiana (IOSI) · Bellinzona, Switzerland
  • TUCARE Bülach AG · Bülach, Switzerland
  • Kantonsspital Baselland · Liestal, Switzerland
  • HOCH Health Ostschweiz - Kantonsspital St. Gallen · Sankt Gallen, Switzerland
  • Spital Limmattal · Schlieren, Switzerland
  • Spital STS AG · Thun, Switzerland
Show 5 removed
  • Kantonsspital Baselland · Bruderholz, Switzerland
  • Kantonsspital - St. Gallen · Sankt Gallen, Switzerland
  • Spital Thun · Thun, Switzerland
  • EOC Istituto Oncologico della Svizzera Italiana (IOSI) · Viganello, Switzerland
  • KSW Kantonsspital Winterthur · Winterthur, Switzerland
Oct 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Kantonsspital Aarau · Aarau, SwitzerlandContact w•••@ksa.ch · •••5580→a•••@ksa.ch · •••6103Contact person changed (no phone or email listed)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    6 sites added, 5 sites removed
    Show 6 added (6 Switzerland)
    • EOC Istituto Oncologico della Svizzera Italiana (IOSI) · Bellinzona, Switzerland
    • TUCARE Bülach AG · Bülach, Switzerland
    • Kantonsspital Baselland · Liestal, Switzerland
    • HOCH Health Ostschweiz - Kantonsspital St. Gallen · Sankt Gallen, Switzerland
    • Spital Limmattal · Schlieren, Switzerland
    • Spital STS AG · Thun, Switzerland
    Show 5 removed
    • Kantonsspital Baselland · Bruderholz, Switzerland
    • Kantonsspital - St. Gallen · Sankt Gallen, Switzerland
    • Spital Thun · Thun, Switzerland
    • EOC Istituto Oncologico della Svizzera Italiana (IOSI) · Viganello, Switzerland
    • KSW Kantonsspital Winterthur · Winterthur, Switzerland
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Kantonsspital Aarau · Aarau, SwitzerlandContact w•••@ksa.ch · •••5580→a•••@ksa.ch · •••6103Contact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07020065
Lead sponsor
Swiss Cancer Institute
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Apr 10, 2026
Primary completion
Sep 2028 (estimated)
Completion
Sep 2030 (estimated)
Last update
Oct 28, 2026

Study contacts

Gisela Müller
Contact
trials@swisscancerinstitute.ch
+41 31 389 91 91
Laetitia Mauti, MD
study chair · Kantonsspital Winterthur KSW

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carboplatin

Start the discussion